WHWK
Whitehawk Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.01
+4.15%Year over year
Reported trailing growth
- Revenue
- -100.0%
- EBITDA
- —
- EBIT
- +15.9%
- EPS
- —
- Free cash flow
- +28.1%
- Operating cash flow
- +27.4%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +20.1%
Three-year CAGR
- Revenue
- -22.3%
- EBITDA
- +68.3%
- EBIT
- -69.6%
- Net income
- +67.7%
- EPS
- +86.0%
- Free cash flow
- -60.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026